Moleculin Biotech, Inc. (MBRX) Key Metrics
MBRX valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $5.7M
- Enterprise value
- $3.7M
- P/E (TTM)
- 0.0
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 0.9
- EV / EBITDA
- 0.5
- Dividend yield
- —
- Beta
- 2.00
MBRX key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsMBRX returns How much profit the business earns on the capital it uses.
MBRX financial health Debt, liquidity and how easily interest is covered.
MBRX efficiency & capital use Working capital cycle and where the cash goes.
MBRX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
MBRX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
MBRX cash returned to shareholders
MBRX key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Share price at fiscal year-end | $3.31 | $42.50 | $321.90 | $397.50 | $697.50 | $1,793.47 | $2,058.97 | $2,340.00 | $4,185.00 | $5,130.00 |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −319.8% | −135.8% | −76.1% | −44.3% | −32.8% | −103.7% | −88.5% | −75.7% | −61.1% | −55.2% |
| Return on invested capital (ROIC) | −457.7% | −797.8% | −371.7% | −272.8% | −322.8% | −380.0% | −220.9% | −137.8% | −67.8% | −61.8% |
| Return on assets (ROA) | −171.9% | −78.9% | −62.3% | −41.0% | −28.1% | −63.8% | −58.9% | −60.8% | −54.7% | −47.8% |
| Return on tangible assets | −305.7% | −376.7% | −110.0% | −62.7% | −21.8% | −96.4% | −93.7% | −140.8% | −117.6% | −74.9% |
| Financial health | ||||||||||
| Total debt | $359,000 | $478,000 | $574,000 | $451,000 | $159,000 | $277,000 | $379,000 | $180,000 | $503,000 | $296,412 |
| Cash & short-term investments | $8.9M | $4.3M | $23.6M | $43.1M | $70.9M | $15.2M | $10.7M | $7.1M | $7.7M | $5.0M |
| Net debt | −$8.5M | −$3.8M | −$23.0M | −$42.7M | −$70.7M | −$14.9M | −$10.4M | −$7.0M | −$7.2M | −$4.7M |
| Debt / equity | 0.02 | 0.08 | 0.02 | 0.01 | 0.00 | 0.02 | 0.02 | 0.01 | 0.03 | 0.02 |
| Debt / assets | 0.02 | 0.03 | 0.02 | 0.01 | 0.00 | 0.01 | 0.02 | 0.01 | 0.03 | 0.02 |
| Current ratio | 1.41 | 0.97 | 3.86 | 9.46 | 20.02 | 5.89 | 3.78 | 2.06 | 3.75 | 3.88 |
| Quick ratio | 1.41 | 0.97 | 3.86 | 9.47 | 20.03 | 5.25 | 3.16 | 2.06 | 3.75 | 3.88 |
| Interest coverage | — | — | — | -19.0 | -3.2 | — | -2.1 | — | — | -89.9 |
| Working capital | $2.8M | −$165,000 | $19.5M | $40.8M | $68.9M | $14.3M | $9.9M | $4.1M | $6.1M | $3.9M |
| Invested capital | $6.5M | $2.2M | $3.1M | $9.5M | $8.2M | $3.0M | $5.2M | $7.3M | $9.9M | $10.2M |
| Tangible asset value | $3.9M | −$5.2M | $14.9M | $41.0M | $67.8M | $6.7M | $4.4M | $3.1M | $6.0M | $3.8M |
| Net current asset value | $2.6M | −$5.8M | $14.1M | $40.4M | $67.4M | $5.9M | $3.8M | $2.7M | $5.9M | $3.8M |
| Capital allocation | ||||||||||
| Dividends paid | $104,000 | — | — | — | — | — | — | — | $0 | $0 |
| Share buybacks (net) | — | — | $25 | $23,000 | $23 | $17 | $0 | $0 | $0 | $0 |
| Capex / revenue | — | — | — | — | — | — | — | — | 311.1% | — |
| Capex / depreciation | 0.00 | 0.10 | 0.98 | 0.52 | 0.12 | 1.88 | 0.26 | 6.13 | 1.56 | 3.48 |
| Stock-based compensation / revenue | — | — | — | — | — | — | — | — | 7,855.6% | — |
| R&D / revenue | — | — | — | — | — | — | — | — | 50,500.0% | — |
| SG&A / revenue | — | — | — | — | — | — | — | — | 45,444.4% | — |
| Efficiency | ||||||||||
| Days of inventory on hand | — | — | -31.6 | -55.1 | 1,274.0 | 2,605.6 | 4,358.3 | — | — | — |
| Days payables outstanding | 11,229.8 | 6,558.4 | 6,600.2 | 2,843.5 | 1,749.9 | 2,101.6 | 3,353.1 | 5,517.9 | 12,257.9 | 18,785.7 |
| Receivables turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
| Payables turnover | 0.03 | 0.06 | 0.06 | 0.13 | 0.21 | 0.17 | 0.11 | 0.07 | 0.03 | 0.02 |
| Inventory turnover | — | — | — | — | — | 0.14 | 0.08 | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $13,500 | $59,500 | $60,500 | $33,500 | $23,000 | $6,000 | $33,500 | $56,000 | — | — |
| Average payables | $2.8M | $2.3M | $2.3M | $1.7M | $1.2M | $1.6M | $1.7M | $1.0M | $604,500 | $317,143 |
| Average inventory | — | — | −$11,000 | −$33,500 | $907,500 | $2.0M | $2.2M | — | $0 | $0 |
| Intangibles / total assets | 50.4% | 65.9% | 29.2% | 19.4% | 13.3% | 38.2% | 44.2% | 56.9% | 57.2% | 68.0% |
Computed from MBRX's annual financial statements (latest annual report filed March 18, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
MBRX valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 0.0. Moleculin Biotech earned a return on equity of −319.8% and a return on invested capital of −457.7% in fiscal 2025. It ended the year with $0.4 million of debt and $8.9 million in cash and short-term investments, a net cash position of $8.5 million. It returned $0.1 million to shareholders: $0.1 million in dividends and $0 in share buybacks.
See the MBRX income statement, the MBRX chart for price history, or the MBRX stock overview for the latest quote and news.
MBRX key metrics FAQ
What is Moleculin Biotech's P/E ratio?
Moleculin Biotech's trailing P/E ratio is 0.0 based on the last twelve months of earnings (as of October 17, 2026). At the end of fiscal 2025 it was —.
What is Moleculin Biotech's return on equity?
Moleculin Biotech's return on equity (ROE) was −319.8% in fiscal 2025: net income of -$33.6 million on average shareholders' equity of $10.5 million.
What is Moleculin Biotech's ROIC?
Moleculin Biotech's return on invested capital was −457.7% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Moleculin Biotech have?
Moleculin Biotech had total debt of $0.4 million at the end of fiscal 2025, a debt-to-equity ratio of 0.02 and more cash than debt.
What is Moleculin Biotech's current ratio?
Moleculin Biotech's current ratio was 1.41 at the end of fiscal 2025: current assets were 1.41 times current liabilities.